Imaging test for clear cell kidney cancer before surgery
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a special imaging agent (89Zr-TLX250) to help doctors see clear cell kidney cancer during PET/CT scans. It is for people in China who have a single small kidney mass and are already scheduled for surgery to remove it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and living in mainland China.
- You have a single kidney mass 7 cm or smaller that needs to be removed by surgery.
- You are scheduled for that surgery within 90 days of receiving the study imaging agent.
- You have not had recent cancer treatments (like chemotherapy or radiation) in the last 4 weeks.
- You have not received certain antibody treatments made from mouse proteins in the past 5 years.
- Your kidney function must be good enough (GFR above 45).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new PET/CT scan that uses a special tracer to find clear cell kidney cancer. If you are scheduled for kidney tumor removal, this scan may help your surgeon see the cancer more clearly before surgery.
This trial uses a special imaging scan (68Ga-C1 PET/CT) to see kidney cancer more clearly. It helps doctors find and understand clear cell renal cell carcinoma, a common type of kidney cancer.
This trial tests whether a special PET/CT scan (68Ga-NY104) can help guide radiation therapy for people with clear cell kidney cancer. The goal is to make radiation more precise and effective for treating tumors that haven't spread too much.
This trial tests a special PET scan to see if it can better find leftover kidney cancer after surgery compared to a standard CT scan. You may qualify if you had kidney cancer surgery within the last 4-16 weeks and are at high risk of the cancer coming back.
This Phase 1 study tests whether a special PET/CT scan drug ([18F]PT2385) can help doctors see kidney cancer and related tumors. It may help guide diagnosis and treatment decisions, especially in people planning surgery or starting belzutifan.
This early-stage trial tests a new type of imaging scan (called PET) that uses a special tracer to help doctors see tumors better. The scan targets a protein called CAIX that appears on many cancer cells, which may help with accurate diagnosis and staging.
Hear when a new Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.